• Skip to primary navigation
  • Skip to main content
  • Skip to footer
  • About
  • Our Products
    • Restoret
  • Team
EyeBio

EyeBio

  • Business Development
  • News
  • Contact

Back to Team

Mike Davies

Chemistry, Manufacturing, and Control (CMC) Lead, Drug Development

LinkedIn

Mike joined EyeBio as Chemistry, Manufacturing, and Control (CMC) Lead, Drug Development in 2023. In this capacity, Mike is responsible for the development of all CMC related aspects of the pipeline post candidate confirmation.

Bringing over 25 years of experience in the biotechnology industry, with multiple successful IND and MAA/BLA submissions across different biological modalities, Mike is an expert in both CMC and drug development.

Previously, Mike was Head of Analytical Services at Lonza Biologics, VP of Protein Sciences at F-star, and has also worked to support a diverse range of biotechnology companies with Protein Science, CMC, and IND and BLA projects including recombinant proteins, mAbs, Fc fusion proteins, bi-specific antibodies, vaccines, and ATMPs.

Mike received B.Sc. in Biochemistry from Lancaster University.

Footer

Contact Us

Please fill out the brief form below with any questions or inquiries, and a member of our team will connect with you soon.

Business Development

EyeBio is bringing disruptive innovation to the field of ophthalmology. We actively seek to expand our pipeline of promising investigational therapies, and we welcome inquiries regarding in-licensing and acquisition of assets into our portfolio.

To learn more, please contact Sarah Milsom, Chief Operating Officer of EyeBio, at s.milsom@nulleyebiotech.com.

Privacy Policy
Terms of Use
Cookie Policy
Accessibility Statement

EyeBio

LinkedIn

Copyright © 2022 EyeBio

logo
  • About
  • Our Products
    • Restoret
  • Team
  • Business Development
  • News
  • Contact